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Tourette syndrome is a complex neurodevelopmental disorder that causes significant 
morbidity for pediatric and adult patients and is present in up to 1% of the population. Genetic, 
functional and volumetric analyses suggest that the core neuropathology of Tourette syndrome 
resides within the dysfunctional cortico-striato-thalamo-cortical circuitry of the basal ganglia. 
Patients can have 5% smaller striatal volumes when compared to age-matched controls and up to 
60% reductions in small populations of regulatory interneurons concurrent with severe clinical 
symptomatology. These interneurons are thought to regulate the immense cortical input that is fed 
into the striatum and modulate depolarization of neighboring medium spiny neurons as they form 
output to the globus pallidus. The goal of this work is to recapitulate interneuron loss in patients 
with severe tics and create an animal model for Tourette syndrome.  
Our group combined the regional specificity of stereotactic plasmid delivery with the 
cell-type specificity of transgenic cre mice in order to induce the expression of diphtheria toxin 
receptor in only those striatal interneurons genetically engineered to express cre-recombinase. 
Recombination of a lox-flanked diphtheria toxin receptor gene will activate protein production 
only in these interneurons, inducing receptor expression and then selective apoptosis after 
systemic diphtheria toxin administration. This system allows the behavioral consequences of 
interneuron ablation to be studied aside from perioperative inflammation of virus injection and 
with the temporal control of distant intraperitoneal diphtheria toxin injection. 
Pre-pulse inhibition is the ability to reduce the ‘startle’ response to a stimulus of high 
amplitude when another stimulus of lower intensity is given immediately beforehand. It is a 
quantitative behavioral assay that is deficient in patients with Tourette syndrome and mice treated 
with high dose amphetamines. Its neurocircuitry is thought to be based in the syncytium of the 
striatal interneurons of the basal ganglia, and deficiencies of behavioral inhibition are thought to 
lie along the spectrum of sensorimotor-gating abnormalities inherent to Tourette syndrome. 
We demonstrated consistent diphtheria toxin receptor expression specific to the 
acetylcholine-expressing interneurons of the striatum. After diphtheria toxin was administrated to 
a subset of mice two weeks post-operatively, a reduction in prepulse inhibition was seen as 
compared to the toxin-naive controls in the cohort. The ablation of these cells was confirmed via 
immunohistochemistry of the sectioned striatal tissue and the degree of interneuron loss appeared 
to correlate with behavioral alterations seen on prepulse testing over the course of 7 weeks. 
Future goals of our work include: understanding the downstream neurochemical changes 
that may ensue from striatal interneuron loss, studying the compensatory mechanisms which may 
reverse symptomatology over time, assessing the validity of this model using medications 
classically used to treat symptoms in Tourette syndrome (typical and atypical antipsychotics, α2-
agonists), and ultimately trialing novel therapeutics to better treat patients in the future. 
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I. Introduction 
 
The purpose of this work is to elaborate on a recent finding which posits a 
pathophysiological explanation for the symptoms of Tourette syndrome. Using a 
vector-mediated gene delivery technique to impair key regulatory neurons in the 
striatum, we hope to replicate an interneuron deficiency which is thought to be the 
pathophysiological basis for Tourette syndrome, and create an animal model that 
will allow us to better understand symptomatology. While we try to emulate 
findings discovered in human patients, we are aware that the sheer complexity of 
the disorder limits our model to only a face-valid representation of the difficulties 
that individuals must live with.  We hope that this model will allow us to test novel 
therapeutics that can manage symptoms, understand natural compensatory 
mechanisms that some patients exhibit, and learn more about opportunities to 
intervene early in presentation in order to mitigate the disorder’s course.   
 
Tourette Syndrome 
 Tourette syndrome (TS) is a complex neuropsychiatric developmental disorder 
found in up to 1% of children. (1, 2) Clinical features that establish a TS diagnosis 
include: multiple motor tics, at least one vocal tic, a fluctuating course of symptoms 
which occur each day for the period of at least 1 year, onset before the age of 21, and 
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associated symptoms cannot be explained by any other medical or psychiatric conditions 
such as autism-spectrum disorder, Parkinson’s disease, Sydenham’s chorea or the 
controversial Pediatric Autoimmune Neuropsychiatric Disorder associated with 
Streptococcal Infections. (3, 4, 5)  A qualified observer is necessary to make a diagnosis.  
Chronic Tic Disorder, characterized by either motor or vocal tics (but not both) 
and Transient Tic Disorder, defined as tics present for less than one year, are thought to 
be other Tourette-spectrum disorders with a lifetime prevalence of up to 5% and 20%, 
respectively. (6) Up to 60% of TS patients suffer from comorbid Attention-Deficit 
Hyperactivity Disorder, a disorder characterized by inattentiveness, over-activity, and 
impulsivity, and 30% from Obsessive-Compulsive Disorder, known for the intrusive 
thoughts and repetitive behaviors that lend name to the disorder.  In fact, only 10–20% of 
children with TS are free of a co-morbid disorder. (7, 8, 9) 
Learning disabilities and deficiencies in fine motor control, motor inhibition, and 
habit learning are among the behavioral abnormalities documented in TS. (10, 11, 12) 
The association of these behaviors with the basal ganglia, (13, 14) and the efficacy of 
dopamine D2 antagonists in treating symptoms have suggested that the core of TS 
pathophysiology may lie in the developing mesolimbic system, specifically in the 
striatum, the largest nucleus of the basal ganglia. (15, 16) 
Gilles de la Tourette first described a case series of 9 patients in 1885 who had 
brief, repetitive, stereotyped, and fragmented movements that seemed to mimic isolated 
components of normal behavior. (17)  The elemental unit of Tourette syndrome thus 
became the ‘tic’. Motor tics include eye blinking, shoulder shrugging, head jerking, 
posturing, or self-harming behaviors, or any combination thereof (among many others). 
Vocal tics can include (but are not limited to) throat clearing, yelling, humming, guttural 
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sounds, or more complex arrangements such as in echolalia, palilalia or coprolalia. 
Echolalia matches the processing of a single auditory stimulus with the creation of an 
identical, almost reflexive response, while palilalia matches similarly an entire phrase or 
sentence. (18)  Coprolalia is the spontaneous selection and expression of language from a 
reservoir of inappropriate words, often sensationalized by depictions of TS in the media. 
While it is true that these utterances are non-volitional and largely beyond the 
individual’s control, it is untrue that they are as common as depicted, and they only affect 
around 30% of patients. (19) 
Commonly, tics are noticed by parents first between the ages of 4 and 6 and have 
the highest incidence between the ages of 7 and 9. In fact, by age 11, 96% of patients 
experience symptoms. (20, 21) Motor symptoms progress rostrocaudally, can become 
more complex with age and commonly occur 1-2 years before vocal tics, which often 
occur between the ages of 9 and 11. Tic severity is worst between the ages of 7 and 15, 
but by age 18, 55% of adults experience reduction in symptoms to ‘minimal’ or ‘absent’ 
levels. Comorbid OCD and ADHD symptoms also subside in parallel as children reach 
the end of their teenage years. (22) In fact, only 5% of individuals report symptoms 
worsening after adolescence, and fewer than 20% of children continue to experience a 
moderate impairment of global functioning as a result of their symptoms at age 20. (23). 
TS is understood to be a largely pediatric developmental phenomenon that in some is 
compensated for by mechanisms yet unknown, but in others persists as a beating drum of 
sensorimotor activation. (24)  
 Tics are typically preceded by ‘premonitory urges’, well defined as sensations in 
the anatomical distribution of an oncoming tic, perceived by a patient before they actually 
start ticcing. (25, 26, 27) Premonitory urges are thought to be the awareness of initial 
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internal stimuli sequentially before they manifest into an actual tic, similarly to the 
feeling of an itch before it materializes into a scratch.  Like an itch, premonitory urges 
can be resisted and the corresponding tics thereby temporarily suppressed. (25, 26)    
However, it is very difficult to completely silence a premonitory urge without a tactile 
“response” stimulus or satisfying movement. The awareness of the premonitory urge 
increases with age, and up to 90% of patients are aware of their premonitory urges 3 
years after diagnosis. (28) 
A specialized form of cognitive behavioral therapy, Habit Reversal Therapy has 
shown efficacy similar to our best pharmacological therapeutics and utilizes the 
awareness of this premonitory urge. (29, 30, 31) Patients are taught to first pay attention 
to the onset of their premonitory urge, and complete a competing response movement to 
provide stimulus necessary to silence the urge without performing the tic. Competing 
response movements are practiced, “antagonistic” movements that are incompatible with 
a tic, such as holding the chin to the chest in order to quell an urge for a head jerking tic. 
The efficacy of Habit Reversal suggests that a mechanism may exist for cognitive control 
of the sensorimotor gating abnormalities of Tourette syndrome and which is utilized by 
non-pharmacological therapeutics such as cognitive behavioral therapy.  In fact, tics are 
commonly known to fluctuate with mood, concentration, sleep, and various social and 
environmental factors. (32) TS has come to be understood as far more than just a roster of 
tics, but in fact an intricate system of abnormal sensation and responses which is 
influenced by both the individual and the outside world. 
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Genetic Correlations 
TS inheritance is complex and is the result of yet undefined contributions from 
each parent. (33, 34) 10 to 100-fold increases in TS have been demonstrated in 
individuals who have first-degree relatives with the disorder as compared to individuals 
in the general population, and chronic tic disorder documented in 7% to 22% of 
individuals with first degree relatives who have TS. (35) Monozygotic twins demonstrate 
a 50-70% concordance for Tourette syndrome and 77% for chronic tic disorder, while 
these values are 9% and 23% respectively for dizygotic twins. (36) An association has 
been found with mutations of the gene SLITRK1 on chromosome 13q31.1, which is 
thought to play a role in dendritic growth and neuronal migration. (37)  SLITRK1 is 
expressed in areas commonly associated with TS, such as cortex, hippocampus, thalamic, 
subthalamic and globus pallidus nuclei, striatum, and cerebellum. (38) However, a 
substantial number of individuals with TS do not demonstrate mutations in the SLITRK1 
gene, and therefore it remains an uncommon cause of the disorder.    
Abnormalities in striatal dopamine balance are well-established in Tourette 
syndrome, and have been the basis for treatment with atypical and typical antipsychotics 
such as risperidone and haloperidol. (39, 40) Examination of our genome for 
polymorphisms on genes coding for dopamine-regulating proteins has yielded 
associations between symptomatology and dopamine receptor subtypes found in the 
striatum, globus pallidus, subthalamic nucleus and the substantia nigra. (41, 42, 43, 44) 
During my undergraduate experience at Johns Hopkins, I worked in Dr. Harvey Singer’s 
lab to first describe polymorphisms on the dopamine transporter gene associated with TS 
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in a cohort of 266 individuals with the disorder, as compared to age-matched controls. 
(45)  Despite this evidence, some studies with focused regions of analyses demonstrate 
no association between polymorphisms on certain dopamine receptor genes and the 
tyrosine hydroxylase gene in TS. (46) The genetics of TS, as they relate to dopamine 
regulation and in general are complex and much work remains to be done in order to 
understand what role they play in the genetic predispositions and clinical manifestations 
of this disorder.  
  A recent discovery by researchers at Yale described a family in which 8 
offspring inherited a severe form of TS from their father, who were all found to share a 
common mutation on the gene coding for histidine decarboxylase. (47) This enzyme 
converts histidine to histamine, a neurotransmitter not previously thought to play a role in 
the pathophysiology of TS. As a result of this discovery, a great deal of interest has been 
focused on describing the mechanism by which mutations on the histidine decarboxylase 
gene result in the symptomatology of severe Tourette syndrome.  
 
The Basal Ganglia 
Genetic, functional and anatomical data suggest that the core 
neuropathophysiology of Tourette syndrome resides within the dysfunctional cortico-
striato-thalamo-cortical circuitry of the basal ganglia. (48) The basal ganglia constitute a 
system of nuclei with anatomic origins in the mesencephalon (substantia nigra pars 
compacta and reticulata), the diencephalon (the subthalamus and thalamic nuclear 
targets), and the telencephalon (the caudate, putamen [collectively termed the striatum] 
and the internal and external segments of the globus pallidus). The broad anatomical 
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extent of this system speaks to its integral role in regulating behaviors, thoughts and 
emotions.  
The striatum is composed of the distinct caudate and putamen nuclei, which share 
significant intercommunication across the intervening anterior segment of the internal 
capsule (which contains several additional motor and non-motor tracts), and serves as an 
input nucleus into the basal ganglia. It receives massive cortical input in four classic-
described parallel cortical-subcortical circuits: a motor circuit from the supplementary 
motor, premotor, and primary motor cortices, an occulomotor circuit from the 
supplementary eye fields and frontal eye fields, an executive function circuit from the 
dorsolateral prefrontal and the lateral orbitofrontal cortices, and an emotional/limbic 
component from the medial orbitofrontal cortex, the hippocampus and the nucleus 
accumbens. A point should be made that these tracts are far from the discrete, parallel 
‘loops,’ as they are described above 
heuristically, but rather deeply-
interconnected functional networks 
which cannot be thought of as only a 
collection separate entities, but rather 
as a single, cohesive network.  
The caudate and putamen 
project to the globus pallidus (GP) and 
substantia nigra pars reticulate (SNr) 
via the classical direct and indirect 
pathways. In the diagram to the left, blue 
Figure 1. Schematic of the basal ganglia circuitry. Blue 
arrows are inhibitory synapses, red arrows excitatory 
synapses and pink arrows dopaminergic projections. 
Globus pallidus pars externa, GPe. Subthalamic nucleus, 
STN. Globus pallidus pars interna, GPi. Substantia nigra 
pars compacta, SNc. Substantia nigra pars reticulate, SNr. 
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arrows denote inhibitory synapses, the red arrows excitatory synapse, and the pink arrow 
dopaminergic projections. The direct pathway is conceptually thought of as the cortical 
stimulation upon the striatum which directly and selectively inhibits the GPi, freeing the 
anterior nuclei of the thalamus from GPi inhibition in order to promote movement in the 
‘go’ pathway. The indirect pathway is thought of as a ‘no-go’ circuit that inhibits the 
GPe’s inhibition of the subthalamic nucleus, which then stimulates the GPi to inhibit the 
thalamus and prevent movement and thought. The GPi serves as an output structure for 
both circuits and plays a role in coordinating their spatial and temporal convergence, 
before sending output to the anterior thalamic nuclei, which then broadly project back 
onto the cortex to initiate or inhibit action. (49) 
Dopaminergic projections of the substantia nigra onto the striatum facilitates 
movement in the direct pathway via excitatory G-protein-coupled D1 receptors and 
through inhibitory G-protein-coupled D2 receptors in the indirect pathway. When 
dopamine depletion occurs, Parkinsonism characterized by bradykinesia and rigidity 
arises. TS, in contrast, is a hyperkinetic movement disorder and the model outlined above 
clarifies why dopamine D2 blockade, which should increase activity in the indirect 
pathway, is of therapeutic benefit in reducing excessive movement. The regulatory 
control of dopamine at the level of the striatum is thought to play a role in modulating the 
immense executive and sensorimotor information arising from the cortex, and the 
improper balance of this neurotransmitter system, its role on the direct and indirect 
pathways and on the functionality of the striatal circuitry as a whole is thought to result in 
at least some of the symptoms of TS, OCD and ADHD. 
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Striatal Interneurons 
In the late 1990’s, advances in neuroimaging permitted new insight into the 
anatomical pathology of TS. Volumetric MRI scanning of the striata of patients with 
severe TS and their age-matched controls demonstrated a 5% reduction in the caudate 
volumes of the TS individuals. (50, 51) While only a small difference, this consistently 
replicated finding focused attention on the neurocircuitry of the basal ganglia, specifically 
the striatum as a locus of pathology in TS. The distinct populations of neurons and 
interneurons within the striatum were closely studied in the context of TS in order to 
explain the results of these volumetric analyses.  
80% of the human striatum is composed of a single type of inhibitory, 
GABAergic neuron, termed the medium spiny neuron (MSN) (52, 53) MSNs in the 
striatum receive massively convergent input from cortical neurons and are arranged in 
two functional and anatomical compartments. The matrisomal MSNs receive input from 
motor, cognitive and associative systems and comprise the bulk of the striatal mass, while 
striosomal MSNs receive input from limbic and hippocampal areas and are interspersed 
throughout the matrix. The remaining striatal neurons are comprised of at least 3 different 
populations of ‘interneurons’ interspersed among the MSNs. Each expresses various 
intracellular proteins and neurotransmitters which contribute to their classification. These 
include fast-spiking GABA-ergic parvalbumin-positive neurons (FSNs) and 
acetylcholine-containing tonically-active neurons (TANs), which are heavily 
interconnected with neighboring MSNs. FSNs demonstrate burst-like activation with 
stable inter-spike intervals, (54, 55, 56) while TANs are more constitutively activated at 
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baseline, but exhibit variable firing patterns as well. (57, 58) These interneurons 
communicate with one another via gap junctions, potentially forming a functional 
syncytium, and are hypothesized to shape and synchronize MSN activity in response to 
cortical input.  
 FSNs form functionally connected units with each other and silence 25-75% of 
the hundreds of neighboring MSNs during choice-selection tasks in rats. In a study 
published in Neuron, single unit recording electrodes were placed bilaterally in the striata 
of mice and the animals were taught to make left/right decisions to receive a reward. (59)  
MSN-MSN pairs demonstrated highest activation rates when the animal chose to the 
ipsilateral side, and FSN-MSN pairs showed greater activation during contralateral 
selection. While MSN-MSN activation has been described as being a “winner take all” 
phenomenon with interconnection both sparse and unidirectional, FSN-MSN connectivity 
is broad, temporally-linked and perisomatic, and may play a large role in modulating 
global MSN activity.  (60)  
TANs exhibited synchronized pausing of their tonic activation immediately 
before reward receipt in reinforcement experiments, termed “conditioned pause 
response.” (61) TANs also synapse directly onto projections from the substantia nigra 
and stimulate both dopamine release and inhibition with single pulse and repeated pulse 
depolarization, respectively. (62) TAN firing pauses synchronously with burst firing of 
dopamine neurons in behaving animals, speaking to the coordination and interrelatedness 
of these two modulatory signals on striatal activity, and the impact of these interneurons 
on reward conditioning and action coordination in animals.   
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In 2006, Leckman et. al. (55) composed the diagram below to organize the 
information regarding striatal wiring. Massive cortical input from motor, cognitive and 
associative systems synapse onto FSNs and a network of neighboring MSNs located in 
the matrisomal compartment of the striatum. Limbic and hippocampal areas synapse onto 
the MSNs and TANs of the striosomal compartment (SS) of the striatum, interspersed 
within the larger matrix of striatal neurons. While the details of the compartmentalization 
of the striatum are beyond the scope of this thesis, they are described here to simply 
elaborate upon the 
modulatory impact these 
interneurons have on 
striatal output, and 
demonstrate the highly 
complex, interwoven 
anatomy of the various 
functional networks 
which compose the 
striatum and ultimately 
form our behavior.  
 
 
Tourette syndrome and the Striatum 
In 2005, port-mortem analyses of 3 patients with severe TS symptoms 
demonstrated a 50% reduction in FSNs in the caudate nucleus and a 30-40% reduction in 
Figure 2. Diagram outlining the general circuitry of the striatum, its cortical input 
and its output targets. Striosomal MSNs, SS, receive limbic input and matrisomal 
MSNs, MS, receive cortical input. Fast-spiking parvalbumin-positive interneurons, 
FSN, and Tonically-active interneurons, TAN, synapse on both populations of 
neighboring MSNs to mediate output from the striatum. Globus pallidus pars 
interna, GPi. Substantia nigra pars reticulata, SNr. Globus pallidus pars externa, 
GPe. Subthalamic nucleus, STN. Substantia nigra pars compacta, SNc.  
Image removed in consideration of US 
Copyright Law 
16 
 
the putamen. (63) The same study also showed an increase (120%) in the number of 
inhibitory neurons of the GPi. A more recent study replicated the 50-60% reduction of 
FSNs, but additionally demonstrated the loss of cholinergic TANs between striatal 
compartments in 5 patients who had severe TS symptoms. (64) No difference was found 
in the number or distribution of MSNs or in the cytoarchitecture of the striatal 
compartments. The loss of these interneurons in TS was speculated to play a role in the 
dysfunctional pruning of cortical input and the formation of resultant thalamic output, the 
degrees of which lie along the spectrum of disorder associated with Tourette syndrome. 
We aim to model the pathophysiology of Tourette syndrome by recapitulating this 
neuropathological change in mice.  While animal models cannot fully recapitulate the 
consequences of these pathological changes in the human, this model will advance our 
understanding of the disorder and the testing of novel therapeutics.  Similar advances 
have been achieved using neuropathologically-based models of several other 
neuropsychiatric conditions, even in the absence of clear etiological understanding.  For 
example, models of chronic stress and early-onset Alzheimer’s disease have led to 
considerable insight into our understanding of depression and Alzheimer’s, respectively, 
and have provided templates for our hypothesis-driven use of new treatment modalities to 
manage the progression of symptoms. (65, 66, 67) Similarly, significant work has also 
been done to understand Parkinson’s disease utilizing etiologically-neutral models of 
dopamine depletion as induced by administration of the toxin MPTP. (68) This model has 
allowed for the investigation of new pharmacological treatments in Parkinson’s disease, 
as well as the development of non-pharmacological therapeutics such as deep brain 
stimulation. (69) While we have yet to understand how or why these pathological 
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changes occur in TS, having a workable mouse model would provide us the opportunity 
to test novel therapeutic strategies in the future. 
Targeted ablation of striatal interneurons raises daunting technical challenges. 
Genetic targeting using parvalbumin or acetylcholine promoters would have extensive 
effects throughout the central nervous system and periphery, not limited to only these 
cells.  Conversely, local infusion of a nonspecific virus or of a pharmacological agent 
lacks cell-type specific targeting.  The technical constraints of single neuron ablation in 
the living mouse are beyond the capabilities of modern neurosurgical technique. 
We have developed a combination strategy, using viral-mediated gene delivery to 
interneurons in transgenic mice, making these cells uniquely susceptible to apoptosis 
after a systemic toxin injection. Transgenic mice express the cre recombinase in targeted 
populations of interneurons, as well as other cells in the body, using the parvalbumin and 
choline acetyltransferase (ChAT) promoters. Stereotactic viral injections are targeted to 
the striata of these transgenic mice.  As described below, our viral constructs contain a 
simian diphtheria toxin receptor (DTR) gene in a backwards orientation, which is 
inverted and activated only in cells that co-express cre recombinase. Therefore, while all 
infected cells in the target region will express the plasmid, only those that co-express cre 
recombinase will express functional DTR proteins on their surfaces. Consequently, these 
striatal interneurons will be uniquely susceptible to ablation after systemic administration 
of diphtheria toxin (DT), to which murine cells are otherwise resistant. Using this 
previously developed DT/DTR system and virus-mediated gene delivery, we unite the 
regional specificity of stereotactic injection with the cell-type specificity of transgenic 
expression, in order to replicate the prevailing pathophysiological basis for 
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symptomatology in Tourette syndrome.  Timed ablation of these cells using this system 
will also permit serial monitoring of behavioral assays in order to determine any resulting 
functional changes and study them in a development context.  
 
Adeno-associated Virus and Gene Delivery 
These experiments critically depend on recombinant adeno-associated virus 
(AAV), the details of which figure prominently in the technical development of our 
approach, as described below.  AAV was first described in 1965 as a contaminant of 
adeno virus cultures. Co-infection with adenovirus or herpes virus is necessary for lytic 
cycle induction.  Its prevalence is high in the general population, as almost 80% of 
individuals can be seropositive at any given time. It is not known to be linked with 
disease if lone infection occurs, and AAV2 use as a gene therapy vector has already been 
established in human subjects. (70, 71) 
AAV has a small 4.7 kb single stranded DNA sequence with 125 palindromic 
base pair flanking sequences that allow it to fold upon itself in a spiral T shaped 
configuration. (71) Its relatively small genome contains several genes with variable-
splice transcription and their products play multiple roles in viral replication. Its genome 
does not code for a polymerase, and it must therefore hijack a cellular polymerase in 
order to replicate. In fact, its entire genome consists only of a cap (capsid) sequence, 
which undergoes variable splicing in order to create 3 proteins which form the capsid, 
and several rep (replication) genes which mediate both polymerase binding to the 
terminal repeat sequences and DNA integration into the host’s genome during its 
lysogenic phase.  
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During infection, the AAV genome is integrated specifically and consistently on 
chromosome 19q13.3. This behavior is unique among all eukaryotic viruses and results 
from its mimicking of a homologous human DNA sequence in order to find its insertion 
site. This specificity mitigates concerns that arise with other vectors regarding the risk of 
DNA strand breakages from variable insertion into other more critical genes, or at key 
polymerase-binding sites. These properties have made the AAV the most attractive tool 
for clinical transgene therapy to date. 
Much work has been done to develop recombinant AAV technology as a tool for 
gene therapeutics and intracellular protein production. (72, 73, 74) At least 10 serotypes 
have been identified and subtypes 2 and 10 are most commonly used in the CNS because 
of their tropism for neural tissue. Genes that have been substituted for viral proteins show 
stable expression within host cells for significant amounts of time, where it is found as 
either a double stranded integrated sequence, converted from its single stranded plasmid, 
or as a circular exosome, which is also transcriptionally active.  
While its main drawback is a small genome that limits the size of the transgene 
that can be inserted in its plasmid, the safety and efficacy of this emerging technology 
have fueled the use of AAV gene therapy in several mouse models, as well as in human 
phase I and II trials for Parkinson’s disease, cystic fibrosis, hemophilias A and B and 
Canavan’s disease (a fatal pediatric inherited disorder associated with mutations in genes 
regulating aspartic acid metabolism). (75, 76, 77, 78, 79) The promise of this new 
technology to treat and understand human disease has broad implications for the future of 
gene therapy and medicine as a whole.  
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Project Goals 
The goal of this work, which constitutes the first 18 months of a larger multi-year 
project, was to use AAV technology to induce the selective ablation of striatal interneurons 
of the mouse in order to model the pathophysiology of Tourette syndrome, and to begin the 
preliminary behavioral analyses to assess the consequences of these ablations. While the 
DTR/DT system has previously used in mice, it was our task to construct an iDTR plasmid 
that would respond to cre induction. After this was achieved, which required iterative 
modification over several generations of plasmids, we tested our system in vitro in cell 
culture, and in-vivo in glial cells and interneurons. Once stable DTR expression was 
achieved, we aimed to test the efficacy of DT delivery to induce cell death in vitro, in vivo, 
and secondarily through our examination of behavioral effects. Well-established behavioral 
assays of striatum-dependent procedural memory, amphetamine-induced stereotypy, and pre-
pulse inhibition were (and continue to be) used to determine any Tourette-like phenotypic 
effects of the ablation of both parvalbumin-positive FSNs and acetylcholine-positive TANs.  
These behavioral assays are described at greater length below. 
In future years of this project, the predictive validity of this model will be assessed by 
determining the response of observed TS-like behaviors to standard pharmacological therapy 
for Tourette syndrome, including antipsychotics and centrally-acting α2 agonists. The 
response to these medications will establish the predictive validity of this model, setting the 
stage for further work to develop and test novel therapeutics. Parallel efforts will also be 
made to determine the downstream effects of these interneuron ablations on functional and 
neurotransmitter systems, as well as their developmental course when initiated in adolescent 
mice in order to determine the adaptive neurochemical mechanisms that may result. 
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II. Methodology 
 
Plasmid Construction 
 We engineered a recombinant adeno-associated virus to allow for the cre-
regulated expression of the diphtheria toxin receptor (DTR) in targeted cells in vitro and 
in vivo.   
 The cre-lox system functions through the specific enzymatic activity of cre-
recombinase on lox DNA sequences. Cre (causes recombination) is a protein of 343 
amino acids whose catalytic site is on the c-terminus of its 4 subunit domain, similar to 
the ‘integrase’ family of enzymes. Cre cleaves DNA at specific lox sequences (locus of 
X-over P1, first discovered in the bacteriophage P1), which are 34 bp long and contain a 
central 8 bp sequences flanked by two palindromic 13 bp sequences. Cre binds to two of 
these sites and recombines the double stranded DNA via a Holliday intermediate. If the 
two lox-p sites are in opposite orientations, recombination will cause inversion of the 
intervening DNA, while lox-p sequences in the same orientation will induce segment 
deletion. We utilized both of these strategies, as further described below. After 
recombination, Cre unbinds the lox sites and resolvases and ligases quickly re-establish 
competent, contiguous DNA, leaving behind a single residual lox-P site.  
 Plasmid construction began with an AAV-kreb vector, obtained from 
collaborators, which served as the backbone for our construct, contained a transcription 
initiation site, and coded for an ampicillin-resisting beta-lactamase gene used for 
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selection in bacteria during cloning. We were able to integrate into this vector two pairs 
of oppositely configured lox sites by methods described below, and ligate in between 
them an inducible DTR cassette. Our first step was to create a sufficient supply of this 
vector for our future work. 
The plasmid was transformed into Invitrogen One Shot® Top10 chemically-
competent  E.coli  (Invitrogen, California), heat shocked at 42° for 30 seconds to promote 
internalization of the DNA, and left to shake 1 hour before the bacteria were plated on a 
ampicillin-containing LB-agar plate. Viable colonies were taken from the plate after 48 
hours and inoculated into 1ml Invitrogen Gibco® LB broth, left to shake for 8 hours, then 
diluted into 100ml broth and left to shake overnight under antibiotic selection. Bacterial 
cells were then harvested by centrifuge at 6000g for 15 minutes and the resulting pellet 
was then transferred to an Endofree® Plasmid Purification Kit (Qiagen, Maryland) for 
retrieval of an adequate supply of the plasmid for our subsequent experiments.  
 A gene for green florescent protein gene, EGFP, was obtained from collaborators 
and was replicated performing PCR amplification on a standard reaction mixture of 
DNTPs, H2O, Taq buffer, Taq polymerase, and a primer set which would read the AscI 
cleavage site on one of its ends and the NheI, HpaI, NdeI sites on its other. The AscI and 
NheI sites would be used to integrate this sequence into the AAV vector. After PCR, the 
reaction mixture was placed in a 1.5% supra sieve agarose gel and run at 100mv for 90 
minutes. The gel around the electrophoresed band of proper length was excised from the 
whole gel and a Quiaquick® Gel Extraction Kit (Quiagen, Maryland) was used to extract 
the DNA from the agarose.  
23 
 
The AAV vector and the EGFP PCR product were then placed in 2 separate 
reaction mixtures of 1 microliter (µl) each of AscI and NheI restriction enzymes, 2 µl of 
NEB4 buffer, 0.2 µl of BSA buffer and 17 µl of water each for a total reaction mixture of 
20µl. The enzyme-induced cleavage resulted in “sticky” ends for both the vector and the 
EGFP gene, and the vector was treated with 0.5 ul CIP (calf intestinal phosphatases) for 1 
hour at 37 degrees to prevent autoligation onto itself.  Gel electrophoresis was then 
performed in 1% agar at 110 mv for one hour on both mixtures in order to separate out 
the purified AAV vector and EGFP gene. Each was extracted and combined in a reaction 
mixture containing 1µl each of a T4 ligase and its buffer in water for 4 degrees overnight 
in order to induce ligation of the sticky ends of the gene into the vector. The products 
were electrophoresed, extracted and then transformed into commercial stbl3 E. coli 
(Invitrogen One Shot®) via heat shock, shaken and then plated onto an ampicillin-
positive agar plate at 37 degrees overnight. After centrifuging, a bacterial pellet was 
transferred to a Quiaprep® Spin Miniprep Kit so that the plasmid product could be 
purified. Enzymatic testing with AscI, HpaI and NdeI, and primer pair matching across 
ligation sites demonstrated a single fragment of the expected transcript length via both 
PCR and electrophoresis. 
We next obtained a DTR gene from another adjacent lab. A sequence was added 
to this gene by Meiyu Xu coding for flag (flu antigen) so that this small amino acid chain 
would be translated at the end of the DTR protein and serve as a target for high-affinity 
anti-flag antibodies used to detect the DTR protein during immunohistochemical analyses 
of cells and tissue. The new DTR-flag gene was replicated via PCR using primer pairs 
which bound to sequences at either of its ends, one containing an HpaI site and the other 
an NdeI site. The mixture was placed in a Biorad C1000 Thermo cycler at an annealing 
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temperature of 55 degree for 30s, at 32 cycles and the product was then incubated with 
HpaI and NdeI enzymes at 37 degrees for two hours. The use of this restriction enzyme 
pair would allow for insertion of the DTR-flag gene into the larger plasmid in the desired 
reverse orientation relative to the direction of transcription. The AAV-EGFP plasmid was 
then lysed with the same restriction enzymes set, both vector and insert ligated (with the 
addition of Vaccinia topoisomerase I for higher efficiency), and the product transformed 
in stbl3 E. coli and purified. Restriction enzyme testing (NheI and NdeI), as well as 
whole plasmid sequencing confirmed the proper integration of the DTR gene and 
demonstrated a new AAV-GFP-DTR-flag plasmid (iDTR2).  
Once construction was confirmed, we used an Endotoxin-free® maxiprep kit to 
harvest a large yield of replicated iDTR2 plasmid for use in the transfection of PC12 
cells.   An aliquot of the plasmid was also taken and titrated to a concentration of 1x1012 
genomic copies per ml and sent to the Salk Institute (California) for packaging in an 
rh10AAV vector. As we waited for the recombinant virus, in vitro testing in 
pheochromocytoma (PC12) cells proceeded.   
 
Cellular  Transfection 
 The PC12 line of cells is derived from a pheochromocytoma of the adrenal 
medulla of the rat. Upon administration with NGF, cells begin forming dendritic 
arborizations, start to resemble sympathetic neurons and form vesicles of dopamine and 
norepinephrine. It has been a well established neural cell line since its first description in 
1976.  (80) 
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 A 1ml aliquot of PC12 cells (Sigma-Aldrich, St. Louis, MO) were thawed from 
deep freeze and diluted in 10ml serum-positive Invitrogen Gibco® Optimem I growth 
media in a Falcon tube. The solution was centrifuged at 200g for two minutes and the 
supernatant was removed. The pellet was resuspended in 10ml growth media and plated 
on a CellBIND® surface cell culture dish (Corning, NY). Cells were visualize under the 
light microscope and left to incubate at 37 degrees celcius and 5% CO2 for 48 hours. 
 Cells were passaged every 2-3 days by first confirming their adherence to the 
collagn coated plate, suctioning their media, washing them with 5ml PBS and then 
removing their adherence to the plate by bathing them in 1ml of Invitrogen Gibco® 
TrypLE-express trypsin. After the cells sat for 2 minutes, they were observed under the 
microscope and shaken gently to detatch any still adherent cells. 5 ml of growth media 
was added and the suspension was pipetted into a new falcon tube. The solution was 
contrifuged and the supernatant vacuumed. The cell pelette could now have been diluted 
to any concentration, plated on collagen-coated microscope slides, and transfected with 
various plasmids. 
 For transfection, cells were plated at a concentration of 1x105 cells/ml onto a 
collagen coated microscope slide partitioned in 4 equal sections. The cells were left to 
incubate overnight in order to promote adherence to the slide and acclimation to the new 
media. When 80-90% confluence of cells was achieved in each slide section, transfection 
proceeded.  First, 1 or 2µl of iDTR2 plasmid was added to an eppendorf tube  containig 
100µl of optimem media. For certain slide sections, 1ul of our GFP-cre containing 
plasmid (the cre source which contained a green marker) was also added. A PUC17 
plasmid, an inert strand of DNA was added as needed to ensure that the same amount of 
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DNA was included into each slide section. For each section, either iDTR2 and PUC17, 
GFP-cre and PUC17, or iDTR2 and GFP-cre was added to a 100µl aliquot of growth 
media. The mixtures were left to sit for 5 minutes, while 4ul of Invitrogen lipofectamine 
LTX® was added to a separate 100µl of growth media. (Lipofectamine is a lipid-based 
compound used to shuttle DNA into cells in a nonpolarized form.) 
 The DNA/media and Lipofectamine/media mixtures were then combined after 5 
minutes and left to sit at room temperature for an additional 30 minutes. This facilitated 
the binding of the lipofectamine to the DNA and each mixture was then added to its 
respective cell section. After 48 hours, flourscence was observed under a microscope in 
order to detect green from either the EGFP gene of the iDTR2 cassette or from the GFP-
cre plasmid in selected cells, and demonstrate the absence of fluorescence under control 
conditions. 
 The general form of our transfection experiments included the 8 different 
experimental groups outlined in chart 1 below.  The first set of cells served as controls 
and were not treated with any DNA. The second set were transfected with the inert 
PUC17 plasmid and GFP-cre, and the third with the iDTR2 plasmid and PUC17. The 
Chart 1. Experimental design of analyses testing the DTR/DT system in transfection of PC12 cells with cre, iDTR 
and PUC17 plasmids. Each cell represents a well of PC12 cells transfected with the plasmids indicated, and 
subsequent exposure to DT. 
 Group 1,2 Group 3,4 Group 5,6 Group 7,8 
DT +   No DNA PUC17+cre iDTR+PUC17 iDTR+cre 
DT -    No DNA PUC17+cre iDTR+PUC17 iDTR+cre 
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final group had both the iDTR2 and cre plasmids transfected. Multiple slides were made 
of this form and then to a subset DT was subsequently added.  
 Cells were immunostained at various time intervals after transfection and DT 
administration in order to detect intracellular proteins (DTR, caspase proteins as 
apoptosis markers) or then run in a cell death assay in order to observe the relative cell 
viability between different experimental conditions.  
  
Apoptosis Assay 
 Half of the cells used for each apoptosis assay were treated with DT in 
concentrations from 1nM to 1µM, as these doses have been reported to be efficacious in 
inducing cell apoptosis in DTR-transfected cells (81). Reagents from an MTT cell death 
assay kit were added to the media of all cells and colorimetric analysis was performed to 
test for cell viability. The MTT assay works by detecting the amount of remaining viable 
intracellular enzymes (hexosaminidases); the greater the number of viable proteins, the 
greater the color change to a deep purple, while the greater the number of apoptotic cells, 
the weaker the absorption of the purple by the spectrophotometer.  
 Cells were grown in Corning® CellBIND® surface 96-well plates and transfected 
with plasmids under multiple conditions as outlined above (12 wells/condition). They 
grew for 48 hours and a percentage began expressing visible GFP on fluorscent 
microscopy. Two days later, they were washed in PBS and the media changed. DT was 
added to the cells the following day and left in the media for 4 hours. MTT (3-(4,5 
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was then added to the mixture. 
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(Roche Pharmaceuticals, Mannheim, Germany) MTT is a yellow compound which, when 
reacted on by hexosaminidase, is converted to purple formazan, changing the reaction 
mixture color. MTT was placed on the cells for 4 hours, and then a buffer solution was 
added overnight which assists in dissolving the insoluble purple formazan into the 
reaction mixture. The following day, the absorbance of the colored solution at 562 nm 
was measured by a Gen 5® spectrophotometer. The relative absorbance of this 
wavelength is inversely correlated to the number of apoptotic cells by this measure.  
  
Stereotactic Virus Delivery 
 Surgical procedures were performed in full compliance with IACUC protocols 
and every effort was made to optimize the peri-operative care of the animals. A log was 
kept documenting the details of each procedure,  animals were monitored closely for 
several days post-operatively and saline/dextrose supplementation was managed 
judiciously, if it was warranted. Every effort was made to minimize any pain or harm to 
the animals studied in our analyses. 
 A dedicated surgical procedure room was prepared in a sterile manner. Mice were 
transported to this space and given several minutes to acclimate. Each was injected 
intraperitoneally with 5mg/kg of the anxiolytic rimodyl at a volume of 0.5ml at least 15 
minute before any other procedure was performed. A viral vector at a concentration of 
1x1012 GC/ml (or saline for controls) was drawn into a 0.5µl Hamilton syringe.  After 15 
minutes, the mice were injected with ketamine/xylazine intraperiotnealy at a 
concentration of 100mg/10mg/kg in a volume of 0.3ml. After anesthesia was confirmed 
by a tail pinch with forceps, the mice’s eyes were covered with lubricant in order to 
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prevent dessication. Their scalps were shaved and were positioned and centered in a 
mouth bar and ear holders on a Digital Lab Standard® stereotactic frame (Stoelting Co., 
Wood Dale, IL). The incision site was washed with an alcohol prep pad and a sterile 
razor blade was used to make 2cm mid-saggital incision. Retracting clips were placed on 
the skin and underlying tissue dissected away. The injection syringe was centered at 
bregma, the intersection of the coronal and saggital sutures. The stereotactic frame  was 
zeroed at this point and the needle was translated to the lambdoid suture in order to 
straighten the head position and ensure that rotation in the superior/inferior and 
medial/lateral directions was minimized. The syringe was then returned to bregma, the 
frame rezeroed and two coordinates 0.74 mm anteriorly and 2.3 mm bilaterally in the 
medial/lateral direction were targeted in order to provide a straight trajectory to the core 
of the striata. The mouse was tested for any locomotor response to a mildly aversive 
stimulus at this time and given a small bolus of anesthetic if it was warranted. 
 A high speed drill was used to create a perpendicular 1mm burr hole at this 
position and the injection needle was advanced to a depth of 3.0mm. It was held here for 
a minute before continuous infusion of the virus was started at 0.1 µl/min for 10 minutes 
via programmable Micro4® microsyringe infusion pump (World Precision Instruments, 
Sarasota, FL), for a total volume of 1 µl. After injection was complete, the syringe was 
left in placed for an additional 5 minutes in order to optimize delivery and minimize 
reflux during steady syringe withdrawal. The contralateral side was also injected with 1 
µl of the virus, and all mice were injected subcutaneously with 0.5 ml saline during the 
course of the surgery in order to supplement fluid balance.  
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 The incision was closed with 6.0 nylon suture. Mice were placed in a heated cage 
post-operatively and provided with moistened food and water in containers on the cage 
floor. Each was given sufficient time to recover post-operatively, and supplemented with 
saline or dextrose if they appeared overly dehydrated or lethargic. Mice were returned to 
the animal care facility and monitored daily for several days post-operatively. 
 Wild type, C57BL/6J mice (Jackson Labortatories, Bar Harbor, ME) and our in-
house GS-cre and Chat-cre transgenic mice were injected with various combinations of 
our virus-bound iDTR plasmids in order to demonstrate the utility of our DTR/DT system 
and learn from the behavioral consequences that resulted from its use. 
 
Tissue Preparation 
 For analysis of virus-mediated DTR gene delivery by immunohistochemistry, 
each brain was removed and quickly fixed in a solution of 4% paraformaldehyde/PBS for 
24 hours, and then equilibrated in a 30% sucrose solution for 48 hours.  
 After 48 hours, the brains were brought to a Leica Jung® SM2000R microtome 
and placed on dry ice for a minimum of 10 minutes in order to allow them to solidify. 
The microtome stage was allowed to equilibrate to -16 degrees Celcius using a 
Physitemp® BFS-3MP temperature controller and each brain was postitioned as if the 
mouse was laying supine with the most rostral portion of its head facing the ceiling.  The 
brain was steadied in this position by coating its base in two thin layers of the sucrose 
solution and then the microtome advanced in order to section the striatum in 40 µm-thick 
sections. Each successive slice was placed in series in wells of a Corning 12-well plate, 
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filled with cryoprotectant solution (30% glycerin, 30% ethylene glycol, 0.2x PBS), The 
plates were placed in a 4 degree refrigerator and the slices were then ready for 
immunostaining after being washed with PBS.  
 
Immunohistochemistry 
 Cells, and brain slices transferred to mesh cups using a paintbrush were washed 3 
times in PBS for 5 minutes each. The cells and slices were then blocked in 10% Serum, 
0.2% Triton (Sigma) and 0.1% Tween 20  (Sigma) in PBS for 30 minutes. Another wash 
performed, and the cells/tissue were then bathed in a solution containing PBS, the 
primary antibody (details listed below), 5% serum, 0.2% Triton, and 0.1% Tween 20. 
They were placed in a 4 degree refrigerator overnight. The next day, 3 washes with PBS 
were performed for 5 minutes each and then a secondary antibody was applied in 10% 
serum, 0.2% Triton, 0.1% Tween 20 and PBS. The choice of secondary antibody was 
based on the wavelength of fluorescent emission desired (488=green, 594=red), and the 
antibody’s disimilarity to the primary antibody in regards to species of origin,  so the Fc 
portion of the primary antibody was recognized as foreign. Several subsequent washes 
removed any unbound, free secondary antibody and the specimen was mounted on glass 
slides with Vectashield mounting medium (Vector Labs, Inc, Burlingame CA). The 
preparations were viewed on a Nikon upright flourescent microscope. 
 Primary antibodies used in our analysis of cell cultures and tissues 
transfected/infected with our plasmid included: anti-flag (mouse, Sigma f1804) at a 
concentration of 1:500 in order to detected DTR-flag in culture and tissue, anti-caspase 
(rabbit, Abcam ab44976) at a concentration of 1:1000 in order to detect apoptotic caspase 
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proteins in cell cultures, anti-GFP (chicken, Abcam ab13970) at 1:2000 dilution in order 
to accenuate plasmid induced GFP expression in brain tissue and cells, and anti-chat 
(goat, Chemicon ab144p) at 1:500 in order to detect choline expressing TANs in the 
striatum. Secondary antibodies used to visualize primary antibody binding included: anti-
mouse fluor 594 (Invitrogen, allo32), anti-rabbit fluor 594 (Invitrogen, a11037), anti-
chicken fluor 488 (Invitrogen, all039), anti-goat fluor 488 (Invitrogen), all at 
concentrations of 1:400 in PBS.  
 In some experiments we used 3,3’-diaminobenzidine (DAB) precipitation to 
visualize antibody staining. DAB provides an opaque stain for ready visualization using a 
light microscope and is particularly useful for low-magnification images.  The initial 
washing and blocking steps are the same as above for this VECTASTAIN® Elite ABC 
reagent protocol. The primary antibody is added after 30 minutes of blocking in rabbit 
serum and incubated overnight at 4 degrees. The same primary anti-ChAT antibody is 
used and a biotinylated secondary antibody is added in a 1:500 concentration the 
following day, after two washes to remove any excess primary antibody. After another 
two washes to remove the unbound secondary antibody, the VECTASTAIN® Elite ABC 
reagent is added, which binds to the biotin of the specialized secondary antibody. After 
one more wash, the DAB solution is added; the peroxidase from the ABC reagent reacts 
with it, producing the opaque, insoluble precipitate. The tissues are then washed in water, 
counterstained and mounted on glass slides for analysis.  
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Behavioral Analyses 
 The design, production, and testing of our DTR plasmid in vitro and in vivo took 
more that the allocated year for my participation in this project, but because of a strong 
interest in this project, I injected our iDTR3 virus (described below) into the striata of  
transgenic ChAT-cre mice (later treated with DT) on which we could pilot our behavioral 
analyses.  
 Pre-opretaive and post-operative mice were brought to a dedicated room with a 
SRA-Lab Pre-pulse Inhibition chamber (SD Instruments, San Diego, California). The 
chamber consisted of a 6” (L) x 2 1⁄4” (internal diameter) Plexiglas tube on a stage under 
which a piezoelectric accelerometer was attached. The chamber was both illuminated and 
sound attenuated, and a speaker providing both high and low amplitude stimuli was 
located 33mm directly above the cylinder.  Mouse movements were detected and 
transduced by the accelerometer and then digitized and stored on an attached computer 
via a compatible Startle program (SD Instruments). Pre-pulse programing and testing was 
performed according to a previous described protocol. (82) 
64 startle readings were obtained per mouse, per trial, under 5 different 
experimental conditions: no stimulus, pulse alone, 6 decibel pre-pulse, 12 decibel pre-
pulse and 16 decibel pre-pulse. Broad-band background noise of 65 decibels was present 
throughout. The trial began with a 5 minute acclimation period, after which a set of 
pulse-only trials were used to obtain baseline startle readings. These trials consisted of 
the background noise pierced by a sudden 120 decibel pulse, with subsequent recording 
of the startle response. Afterwards, randomized pulse only, pre-pulse (all decibel levels), 
and no pulse conditions were delivered over the course of 21 minutes, with an average 15 
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second breaks between each trial. The pre-pulse rounds consisted of 20ms long prepulses 
delivered at each of the three decibel levels, 200 ms before the startle stimulus. The 
mouse’s startle amplitude was recorded for up to 50 ms after the 120 decibel pulse was 
delivered, in order to obtain a startle response only immediately relevant to the delivered 
stimulus. The no stimulus conditions consisted of only the broad band background noise 
and were used as a measure the mouse’s baseline activity.  
 Data was then collected for each mouse and formatted to produce an output file in 
Excel which documented baseline, mean and peak velocity measurements. Time points 
for maximal startle response and soonest response after pulse delivery were also 
documented. These data were ordered by trial, and mean startle amplitudes at baseline 
and between pre-pulse conditions were calculated. Pre-pulse inhibition was computed as 
the percent difference in startle amplitude for a given condition as compared to the 
baseline startle response. Lower startle amplitudes in the pre-pulse conditions indicated 
an inhibition. Data was aggregated across multiple experimental conditions and groups in 
order to provide mean startle and pre-pulse inhibition values for each mouse and for each 
group. Statistical distribution was reported as the standard error of the mean. 
  
 
 
 
 
 Figure 3 depicts the first generation DTR plasmid, iDTR1. Its lox sites are in the 
same orientation, which induce segment deletion in the presence of cre, and are denoted 
by the black arrows. A red fluorescent protein (RFP) sequence is downstream to a stop
cassette, both found within an intervening sequence flanked by two lox sites, or ‘floxed’. 
 
In the absence of cre, transcription initiates at the CMV promoter, continues 
through lox 1 to the RFP sequence, and ends upon transcribing the stop cassette. In the 
presence of cre recombinase, the floxed cassette is excised, leaving behind a single lox
site and allowing expression of the iDTR gene. This first generation plasmid was 
developed before my work began on this project. 
function in PCR analysis of fragment length alteration with variable primer set under 
Cre+ and Cre- conditions, as well as adequate RFP expression
not adequately express RFP after in
and thus necessitated a re
 
Figure 3. First generation iDTR plasmid, iDTR1.
III. Results 
 
While it demonstrated expected 
 in transfected cells, it did 
-vivo stereotactic infection of striatal interneurons, 
-working of its construct.  
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-P 
 iDTR2 
Figure 4 depicts our 
constructing and took a lead role in testing both
of cre to invert the sequence between two lox sites in opposite orientations.  This 
inversion is made irreversible through the use of two distinct lox sites, loxP and lox2722, 
as further described below. 
 
Figure 4. iDTR2 plasmid. Dark and light gray rectangles represent two pairs of matching lox sites. After 
recombination, the two unm
 
An elongation factor promoter is depicted most upstream of the construct and 
initiates transcription. Lox2722 (number one) is read upstream to loxP (number two), and 
transcription continues to EGFP, a gen
the cre-negative strand at the top of this image, an inverted, untranslatable DTR sequence 
is then read. Transcription continues through the pairing lox2722 and loxP sites (numbers 
three and four) to WPRE (
stabilization sequence used to enhance transcription 
The plasmid concludes with a poly
is inverted, activating DTR expression and inactivating EGFP.  
second generation plasmid, iDTR2, which I assisted in 
 in vitro and in vivo. It utilizes the ability 
 
atched lox sites remain on the plasmid as labeled.
e which codes for a green fluorescent protein. In 
woodchuck hepatitis post-transcriptional regulatory element)
efficiency in mammalian c
-A site. In the presence of cre, the EGFP
 
36 
 
, a 
ells (83). 
-DTR cassette 
 The double lox sites in this construct render the inversion irreversible.  The 
mechanism of this effect merits further explanation. With one pair of lox sites in 
opposing orientations, the cassette has the 
Therefore in the presence of cre, the cassette with one set of opposing lox sites will be as 
likely to be in the reverse orientation as in the forward direction, as recombination can 
occur continuously.  
Figure 5. Intermediate formed during recombination of the iDTR2 plasmid. As the cassette is recombined, lox sites 
3 and 4 are displaced upstream and lox site 2 downstream on the plasmid.
 
However, with the two lox sites as they are cur
flip of the entire sequence between the dark gray bars (for instance) in Figure 4 will result 
in a dark gray lox site positioned in between two light gray lox sites, as shown in Figure 
5. In addition, the light gray lox s
to its complementing site, number 1. This would result now in the deletion of the 
intervening sequence between the two light gray lox sites, resulting in the removal of the 
dark gray lox site, and the replacement of the entire excised sequence with only a single 
light gray lox site remaining in its place (number 1). Two incompatible lox sites will thus 
remain, one at either end of the now inverted DTR
will stall and thus DTR translation will primarily occur in the presence of cre. 
 
potential to flip back and forth indefinitely. 
 
rently positioned, the result of a 
ite (number 3) will now be in the same direction relative 
-GFP cassette. Segment recombination 
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 To demonstrate that the floxed cassettes recombined in the presence of cre and 
worked as we envisioned, PCR analysis of the plasmid was performed by selecting a 
primer pair that would allow for exponential copying only 
floxed cassette by cre occured
sequence in the backward direction (towards the cassette) and a forward EGFP3F primer 
that would also bind in an upstream direction when the cassette was unflipped. The 
following diagram demonstrates the primer pair and its binding.
 
This relative configuration of primers will cause the PCR transcripts to be 
produced at a linear rate because only by binding to primer 2 will both primer sites be 
available for transcription during the next round of the cycle. The transcription product 
would also be significantly shorter when polymerase binds to primer 1 rather than primer 
2, and these two different bands would be separated out during electrophoresis.  When 
the cassette ‘flips’ in the presence of cre
will result in a transcript that contains both primer sites. The rate of product formation 
increases exponentially, and will result in a single fragments
confirming the recombination of our plasmid. 
Figure 7 demonstrates our primer pair recombination analysis. Each odd
numbered lane contained the plasmid alone, and each even
Figure 6. Second generation iDTR plasmid with primer binding sites for experimental testing of recombination in 
the presence of cre
when recombination of the 
. The primers included one on the woodchuck stabilization 
   
-recombinase, each polymerase binding event 
 of uniform length, thus 
 
-numbered lane contained the 
-recombinase, via the polymerase chain reaction. 
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 plasmid and cre. The final two lanes 
contained cre only and water as a 
control, respectively. The specific 
appearance of a band of the predicted 
length only in the cre-containing lanes 
confirmed that recombination of this 
selected, purified plasmid was 
occuring in response to cre
planned. The activation of DTR by cre 
recombinase in this iDTR2 plasmid 
results in the reciprocal inactivation of 
the GFP reporter gene in 
cre-deficient cells. The entire iDTR2 plasmid is dep
Figure 8. Schematic 
representation of the iDTR2 
plasmid, with the entire AAV 
vector. LoxP and loxp2722 
sites are oriented as shown.
, as 
cre-positive cells, which remained a marker of transfection in 
icted below. 
 
 
 
 
 
 
Figure 7. Electrophoresis gel depicting a transcript of 
uniform bp length only when the PCR reagent mixture 
contained both the second generation iDTR plasmid and 
cre,, demonstrating the ability of our plasmid to undergo 
recombination.  
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 Receptor Detection in Cell Culture
We first tested our iDTR2 constructs 
PC12 cells to confirm the ability of a co
expression.  As with any pilot work, a number of hurdles needed to be overcome in order 
to demonstrate reliable DTR expression in cells. First, while the PC12 grew well on the 
specialized Corning® plates, it did not appear that they were adequately adheren
glass slides (which were used for fluorescent analysis), and thus we developed a protocol 
to coat the slides in type IV collagen, incubate them, and remove the supernatant solution 
in order to promote adherence. The cells began adhering to the sli
characteristic pseudopodia seen under the microscope, which were a marker for surface 
adherence. We then transfected them as per the protocol outlined above.
 The following images are representative of iDTR2 and cre
viable PC12 cells.  
 
 
 
 
 
Figure 9. Transfection of PC12 cells with both GFP
cre and iDTR2 as seen under green (A), red (B) and 
combined (C) fluorescences. An overlappig of red 
and green fluorescence is seen in cells transfected 
with both plasmids ad expressing DTR
A 
 
in vitro, using transient transfections in 
-transfected cre plasmid to activate DTR 
des and producing the 
 
-plasmid transfect
-
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ion of 
B 
C 
 The cells were immunostained with a primary anti
detect DTR) and an anti
demonstrates the GFP which is part of the cre plasmid and serves to indicate the relative 
transfection rate, and some GFP from any unflipped iDTR2 plasmid
of cells appear to be transfected and strong GFP signals are seen indicating adequate 
expression of cre recombinase in these cell. 
under red fluorescence to demonstrate binding of the anti
cells co-transfected with both GFP
cell surfaces. Figure 7C 
also express DTR (via overlapping green and red fluorescence) showing that none of the 
cells that express DTR (red) are free from co
In figure 10, a representative 
iDTR2 or solo cre plasmid transfected cells
demonstrated. The cells that received either a 
single plasmid or no plasmid 
demonstrate the bright red fluorescence seen in a 
subset of the cells in image 9B
detectable flag sequence was being produced in 
these cells. In the solo cre plasmid transf
cells, green fluorescence was demonstrated, as would be expected because of the GFP 
found on the cre-plasmid, but no red fluorescence
the solo iDTR2 transfected cells.
-flag primary antibody (to 
-mouse Alexa fluor 594 (red) secondary antibody. 
. Approximately 30% 
In figure 7B, the same cells are visualized 
-flag antibody onto a subset of 
-cre and iDTR2, and which now express DTR on their 
demonstrates the relative number of cre-transfected cells that 
-transfection with cre (green). 
image of background red fluorescence in solo 
 is 
at all did not 
. Thus, no 
ection 
 was seen. A weaker green was seen on 
 
Figure 10. Representative image of single
plasmid transfected cells, or cells not transfected 
with DNA, stained with anti
41 
Figure 7A 
 
-
-flag antibody. 
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Under higher magnification, we can see the broad expression of the DTR around 
the cell surface of iDTR and cre co-
transfected cells, stained with anti-flag. In 
addition, the localization of the cre GFP to 
the nucleus of some cells allows us to 
clearly demonstrate the expression of both 
signals within the same cell, and the 
specificity of the co-location of the two.  
In sum, these transient transfection 
studies in PC12 cells showed that our 
various iDTR constructs expressed flag-
DTR only in the presence of cre 
recombinase.  We went on to produce 
recombinant virus using these plasmid 
constructs to test their ability to target 
specific populations of interneurons in cre-expressing transgenic mice. 
In parallel to our work with PC12 cells, I formed a collaboration with a researcher 
from another lab to test our iDTR constructs in primary neuronal culture.  Higher 
transfection efficiency and cell stability in these primary cultures, as compared to PC12 
cells, permitted quantitative assays of cell ablation using a colorimetric assay.   
The cultures were prepared by extracting the brains from mouse embryos, 
washing them in a solution of PBS/glucose, adding 5-6 ml trypsin in three washes,  
Figures 11A and 11B. Complementary high power images of iDTR2 and GFP-cre co-transfected PC12 cells 
A 
B 
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dissociating the cells by repeated pipetting, and then plating them on polylysine-coated 
plates at a concentration of ~180,000 cells per well. 1.3 ml growth media was added per 
well and consisted of glucose and glutamine-containing DMEM media, 
penicillin/streptomycin, sodium pyruvate and fetal bovine serum. Growth media was 
changed weekly, Neurobasal (Gibco) was added for cell maintenance, and after 14 days, 
the cells were transfected with our plasmid as per the protocol outlined above.  
 The following images were taken from the primary culture of neurons transfected 
with our iDTR2 plasmid and the 
GFP-cre plasmid. Figure 12 
demonstrates a very high percentage 
of GFP-cre expressing cells, 
indicating a much higher 
transfection efficiency than we were 
able to achieve in the PC12 cells. 
Figure 13 demonstrates a high 
percentage of cells that positively 
express DTR, but also a small subset which do not. This is likely a result of necessitating 
simultaneous transfection of both 
plasmids in order for recombination, 
transcription, translation, and protein 
production and expression to occur as 
planned.  
Figure 12. Neural culture transfected with GFP-cre and iDTR2. 
Green fluorescence was amplified with anti-GFP and is the 
product of the GFP gene on the cre plasmid. 
Figure 13. The same transfected 
neural cells as in figure 12, co-stained 
with anti-flag and viewed under red 
fluorescence. 
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Figure 14. Colocalization of GFP-cre and DTR in 
primary neural culture 
The final image in this series demonstrates the co-localization of green and red 
fluorescence, and GFP and DTR, 
respectively, in the neuronal culture.  
 
From these images, we 
observed that in two different cell 
lines, and in highly controlled 
experimental conditions, we were able to demonstrate selective DTR expression in only 
those cells with the potentiality of being transfected with both the cre and iDTR2 
plasmids. The next task in testing our system was to demonstrate greater cell death in 
response to DT exposure in DTR/cre co-expressing cells than in other, control conditions. 
 
Cell Apoptosis Assay 
 After we documented adequate transfection in our PC12 cells, we began 
conducting cell death assays with DT administration, using the protocols described 
above. With the aid of a spectrophotometer, we were able to quantify the number of 
viable cells that would induce a color change in the reagents of the cell death assay and 
from this measure have quantitative data demonstrating the function of our DTR/DT 
system. The results of this initial work on the transfected PC12 provided uninterpretable 
data, which may have been the result of the instability of this line, even under control 
conditions. The results for cell apoptosis is thus demonstrated for the primary neuronal 
culture. 
 Transfection of primary neuronal cultures had both a higher transfection 
efficiency and a lower level of background cell d
following graph represents the effect of
analyzed using the same commercial cell 
The groups include singly tranfected controls,
administration, a doubly transfected cohort without DT, and our experimental group 
transfected with both plasmids and treated with DT. The cell viability is reporte
to the most viabile cohort, cre+water, and all
viability as compared to this group. Here, we see that cre or DTR transfection alone had 
some effect on cell viability but it only appears to a maximum of 20% cell loss. 
Additionally, the two solo
less. In the group transfected with both plasmids, we see a further degree of cell loss, 
approximately 20% below the cre+water group. We understood from our PC12 studies 
Figure 15. Cell death assay performed on a neuronal culture transfected with the iDTR2 and GFP
eath as compared to the PC12 cells.  The 
 1µM DT on these transfected neurons, as 
viability assay intially tested on PC12
 singly transfected groups with DT 
 other groups are reported as percent cell 
-plasmid-plus-DT groups show some cell loss, but at 10% or 
plasmids, and subsequently administered DT. 
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 cells.  
d relative 
-cre 
 that the greater the number of transfected p
secondary to concordant lipofectamine intake and plasmid interference of normal cellular 
function. Finally, we see that the group administered both plasmid and DT showed a 45% 
reduction in number of viable cells
conditions, which was also 25% lower than the iDTR+Cre+water group or lower than the 
effect of DT alone (which appeared to be only 10%). While not total cell loss, which was 
not expected from of our experi
expressed DTR, this provide
loss resulting from the implementation of our DTR/DT system. This provided the 
impetus for us to move forward with
 
In vivo Receptor Detection
 The first stereotactic virus injections were performed using our iDTR2 plasmid, 
which was the first plasmid to be packaged in an AAV vector. The following images 
demonstrate the loss of GFP expression in GS
Figure 6Figure 16. Wild-type and transgenic GS
plasmid in an AAV vector. The loss of green fluorescence in the 
lasmids, the greater potential for cell loss
 as compared to the viability of the other control 
ments demonstrating that not all cre-
d controlled data demonstrating that there was in fact cell 
 our in vivo testing. 
 
-cre mice compared to wild
-cre mice (cre expressed in glial cells) infected with our iDTR2 
GS-cre mice is seen compared to wild
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transfected cells 
-type controls. 
-type mice. 
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 The plasmid, in review, functions by flipping the inner cassette in the presence of 
cre to remove transcription of the GFP gene and flip the DTR gene into a ‘forward’ 
orientation, so it is transcribed instead. GS-cre mice are transgenic mice which express 
cre in all neural tissues. Thus, if we look at the images, the wild type mice (which contain 
no cre in their cells) show clear GFP expression in discretely identifiable cells 
surrounding the virus injection site. However, in the GS-cre mice, the plasmid should be 
recombined in the cre-recombinase-expressing cells, the GFP should become rendered 
non-transcribable and DTR should thus be expressed. In the two right images taken from 
GS-cre mice, there is a distinctly different quality of the fluorescence in which individual 
cells are no longer outlined and some diffuse fluorescence, secondary to the gliosis 
induced by the introduction of a needle into the area, is seen. This was clearly different in 
quality from the GFP expressed in the wild type mice. 
While this plasmid nicely demonstrated the loss of the GFP reporter protein 
during infection of neural tissue, we did not see clear immunostaining of DTR-flag 
expression. Part of this may have been the result of the bulky iDTR-GFP recombination 
cassette (refined in the iDTR3 plasmid) which may have limited the number of properly 
oriented DTR genes that would serve as a template for transcription, or it could have been 
the result of our efforts to refine a DTR-flag staining protocol that worked as well in vivo 
as it did in vitro. Regardless of the cause, we understood that using this plasmid would 
create additional barriers to our progress with our in vivo work, so at this point we 
decided to create the 3rd generation plasmid (iDTR3) in which the recombination cassette 
consisted of only the iDTR gene. This would shorten the plasmid, simplify 
recombination, and hopefully provide us with stronger evidence that DTR was being 
expressed in vivo.  
 iDTR3 
We began constructing the iDTR3 plasmid by 
aliquot of our iDTR2 plasmid
Biolabs) and CIP and ligating
promoter, which has been shown to have  higher transfection rates in other experime
designs. (84). E. coli were transformed, miniprep performed
digested and analyzed for proper fragment length using electrophoresis
plasmid sequencing. A properly constructed plasmid
(to create a supply for in
AAV vector for in vivo experimentation
The improvement of 
recombination and a smaller overall plasmid size for better packaging within our viral 
vector. The concept of its design is 
figures 17 and 18. While it appeared to provide a more striaght
inducing DTR expression, we understood that 
Figures 17 and 18. iDTR3 plasmid. The smaller 
recombination cassette contains only a
under cre control. The whole plasmid sequence is 
additionally similar to the iDTR2 construct but with the 
addition of a CMV promoter instead of the EF
promoter.
copying the DTR-flag
 via PCR,  treating it with klenow fragments
 it into an AAV vector containing a stronger CMV 
, and the plasmid was 
 was purified, copied via
 vitro transfection experiments), and sent for packaging in an 
. 
this construct would be a smaller fragment length 
similar to our iDTR2 construct and is 
forward method of 
 iDTR-flag gene 
-1α 
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 gene from an 
 (New England 
ntal 
 and whole-
 megaprep 
to undergo 
depicted in 
CMV 
 it would be at the expense of an EGFP reporter gene which would serve as our marker for 
transfection and infection efficiency. 
demonstrated to be as efficient as the iDTR2 construct in inducing DTR expression, and 
we therefore pressed on with our work 
 
 
 
 
 
Figure 19. First in vivo injections of our v
 
Figure 19 depicts our first infection of striatal tissue with our newly
shorter iDTR3 plasmid. With our flag staining protocol, were able to demonstrate DTR 
expressing cells immediately surrounding the needle tract in a cohort of GS
Looking closely, staining on the periphery of individual cells can be seen, similar to the 
staining pattern demonstrated in the PC12 and primary neural cells, making us confident 
that membrane-bound DTR was express
capsid-bound plasmid. 
The new iDTR3 plasmid was tested 
to detect DTR expression  in vivo.
 
 
 
 
 
irus-packaged iDTR3 construct. Tissue was stained with 
ing in cre- containing cells infe
49 
in vitro, 
  
anti-flag. 
-packaged, 
-cre mice. 
cted with our 
   Additionally, figure 20
immediately surrounding the injection site, but no staining at its periphery. While this 
nicely demonstrated the specificity of the immunostaining, and led us to believe that we 
were seeing true DTR expres
localized, and we hoped we would be able to
future experiments. We worked to
and by using our newly acquired
infusion rate. 
Images 21 and 22
(with cre expression in choline acetyltransferase cell
plasmid in one of their striata, and saline on the contralateral side
Figure 20. Close-up of injection site of iDTR3 virus demonstrating anti
 demonstrates the staining of DTR expressing cells 
sion, we were unsure as to why the infectivity 
 demonstrate more diffuse infectivity
 this end by increasing the volume of virus injection 
 microsyringe infusion pump for a steady and continuous 
 demonstrate our next experiment in which ChAT
s) were injected 
. ChAT interneurons
-flag staining only at the injection site and not 
at the periphery of the slice. 
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was so 
 in 
-cre mice 
with our iDTR3 
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Figure 21. Anti-ChAT staining of saline-injected striatal tissue. No 
DTR staining is demonstrated in these cells.
were stained with a red 
fluorescent anti-ChAT antibody 
in order to demonstrate the 
distribution of these cells in the 
striatum and green anti-DTR to 
demonstrate any DTR 
expression. In figure 21, the red 
fluorescence of the native ChAT 
cells in the right striatum is 
demonstrated, after this side was 
injected with saline to serve as a control. However, no true green fluorescent anti-DTR 
antibody is staining these cells (the green streaks are artifact seen in all slices). In the 
same mouse, figure 22 shows 
the contralateral striatum where 
virus was injected. In this 
image, we see roughly the same 
distribution and red fluorescent 
staining of the ChAT cells as the 
contralateral, control side. 
However, on this virus-infected 
side, we also see the co-
localization of green fluorescent 
DTR staining on these ChAT interneurons. In fact, there are cells toward the right and 
left sides of the image, beyond the suspected infectivity area, which only demonstrate red 
Figure 22. Anti-ChAT (red) and anti-DTR (green) staining of iDTR3 
virus-injected tissue. 
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staining for choline acetyl- transferase, but not green fluor 488 for DTR, as they may 
have been beyond the range of viral infectivity. Those in the center at the injection site 
are co-localizing the stains for both red and green fluorescence, demonstrating the 
specific expression of DTR only in these cre-expressing, transgenic ChAT interneurons. 
We were confident our iDTR3 plasmid worked to express DTR in vivo. 
 
Neuronal Ablation 
The work thus far was mostly performed during my research fellowship year, and 
as clinical responsibilities drew me away from the laboratory, progress was made to 
confirm neuronal ablation within the stratum and early steps have been taken to show the 
behavioral effects of these ablations.  
In parallel with the development of this virus-mediated ablation strategy, we 
explored a simpler, though messier, strategy to achieve ChAT interneuron ablation in 
mouse striatum.  It is our hope that this will produce convergent results with the virus-
mediated strategy, strengthening the result.  A specialized immunotoxin, anti-ChAT-
saporin, targets the proteinaceous saporin toxin specifically to ChAT-expressing neurons 
to induce cell ablation directly and understand further the behavioral manifestations of 
interneuron loss.  
Saporin is a toxin which was first discovered in 1983 from the seeds of the 
Saponaria officinalis plant, and is also commonly known as ribosome inactivating 
peptide. It removes a single adenine base from the larger unit of a ribosome, completely 
inactivating it. It has been coupled to antibodies and has been used as a targeted 
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immunotoxin in a variety of studies. By purchasing this saporin-delivery ChAT antibody, 
we could test the consequences of the exact phenomenon we were trying to replicate. 
Figure 23 was prepared by a Meiyu Xu demonstrating the unilateral injection of chat-sap 
toxin, with contralateral saline, in a wild-type mouse.  
Using a computerized algorithm for detecting changes in staining gradients, our 
lab was able to test a novel staining technique for detection of ChAT interneurons, while 
clearly demonstrating the consequences of immune-delivered saporin toxin on these 
dispersed interneurons within the striatum, as evidenced by figure 23. Indeed this image 
is what we strove toward with our DTR/DT model, but our focus was still to regulate 
such neuronal ablation using our DTR delivery system so that a timed ablation could be 
performed distantly from operative trauma and nonspecific gliosis (both of which are 
seen in the toxin-infused side in the image above), and so that the developmental and 
Figure 23. Interneuron ablation demonstrated with ChAT-saporin immunotoxin. Saline was injected on 
the left side of this image and toxin on the right. Red and green dots were overlain by a computer 
program to allow for clear tagging of viable cells on either side. 
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compensatory effects of this neuronal ablation, as mediated by our DTR/DT system, 
could be better understood. Our methodology would also allow for us to target different 
neuron types in the future, flexibility that we would not have with this ChAT-sap virus. 
 The initial behavioral comparison of these animals to their saline-injected siblings 
demonstrated some changes in the inhibition of prepulse two weeks post-operatively, but 
the sample size was small, our focus was still to demonstrate these changes using our 
DTR/DT system, and newer PPI data in the most recent cohort of mice injected with our 
iDTR3 virus was subsequently obtained. The immunohistological images of neuronal 
ablation in these mice are demonstrated alongside their behavioral data in the following 
section.  
 
Prepulse Inhibition in Virus-Injected Mice 
The preliminary experiment using our iDTR3 virus (with subsequent DT) 
provided exciting initial correlations between immunohistochemical evidence of neuronal 
ablation and behavioral consequences in PPI, demonstrating that our system worked as 
planned. This experiment was performed in the last two months and is the newest data 
compiled for this project. 
 While our lab was only in possession of nine chat-cre mice, I performed all 
surgeries within a couple days of meeting with Dr. Pittenger to discuss continued 
involvement in this project. Baseline PPI behavioral assays using the exact protocols 
described earlier were performed on all nine mice before undergoing surgery. All were 
injected with 1 µl of the iDTR3 plasmid in an AAVrh10 viral vector bilaterally, for a 
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total volume of 2 µl virus per mouse. Coordinates were the same as previously described 
and no untoward events occurred during any of the surgical procedures or during post-
operatively recovery. 40ng DT was diluted in 300ml saline and injected in five of the 
nine mice immediately after the 2-week post-operative PPI assay (mice #3,4,5,6,7) each 
day for 3 days.  This high dose of DT proved to have non-specific effects on startle 
(which will be described in detail below), problematizing the interpretation of PPI 
changes in these 5 mice. Therefore, at five weeks post-operatively, after obtaining 3 full 
weeks of behavioral analyses for the five high dose DT mice, we decided to inject two of 
the four remaining DT-naïve mice with a lower dose of DT (4ng in 300ml saline, given 
just once to mice #1 and #2). This lower dose of DT proved not to have any of the non-
specific effects on startle but was sufficient to ablate the DTR-expressing interneurons 
(see below). We tested whether this lower DT dose would alter behavior in a specific 
manner by reducing PPI, but not the startle amplitude in response to the loud auditory 
stimulus. Therefore, of the nine original mice available to us in this pilot experiment, five 
had high dose DT injections (40ng x 3 days) at 2 weeks post-operatively, two had low 
dose DT at 5 weeks post-operatively (4 ng x 1 day) and two were only injected originally 
with the virus and not any DT post-operatively (mice #8 and #9) in order to serve as 
controls. 
 PPI was assayed two weeks post operatively, after a pre-operative PPI, and then 
for several additional weeks after DT administration. The results of the prepulse data for 
the five weeks in both groups of mice are shown in graph 1. 
 
 
  
 
Graph 1. PPI data for virus-injected mice. Four mice were not injected with DT, and fiv
dose DT at two weeks post-operatively.
 
First, the data demonstrate an 
remained stably prominent
addition, there was a stepwise increase of PPI for the control mice with increasing 
prepulse stimulus amplitude, as is 
DT, we observed no long term deficits in PPI as a result of the vector
 High-dose DT mice had a lower baseline PPI values as compared to the control 
cohort. This was unfortunately unavoidable due to our limited number of available mice 
and a result of the difficulties in separating mice housed in the same cages into different 
experimental conditions in an attempt to equalize the groups at baseline. The difference
in baseline PPIs between the control and DT mice was most divergent at the 12 db level 
but the standard errors of the mean
e were treated with high
 
improving PPI at two weeks that plateaued and 
 for five weeks post-operatively in the four control mice. In 
commonly seen.  In the controls who never received 
-delivery surgery.
 were overlapping for both of the other two prepu
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, 
lse 
 conditions. At two weeks post
increased for the ‘DT’ cohort and it more closely resembled the two week PPI of the 
control mice. 
 Immediately after the 2
administered to them over the course of three days as outlined above. Therefore, their 
first PPI analysis after DT administration was at 3 weeks. There appears to be a small 
decline in PPI from week 2 to 3 for th
At 4 weeks, this PPI deficit became more pronounced. While there appears to be a slight 
recovery at 5 weeks, it was not quite at baseline levels, and was certainly not near the 
high plateau level as seen w
striking PPI reduction, there certainly appeared to be some effect of DT administration on 
PPI. Looking at the PPI over the course of these weeks for some of the individual DT
injected and control mouse certainly did, however, demonstrate some effect on PPI with 
DT administration on an individualized level. Mouse 3 received DT at the point in time 
denoted by the arrow and mouse 8 was a control
Figure 24. PPI data for individual mice. Mouse 3 was treated after we
8 was not treated with DT at all after iDTR3 virus injection.
-op, before the high-dose DT administration, the PPI 
 week PPI for the five high-dose DT mice, DT was 
ese mice, possibly due to some initial DT effects. 
ith the control mice at this week of analysis.  While not a 
, as shown in figure 24.  
ek 2 PPI as denoted by the arrow and mouse 
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  Unfortunately, an unexpected 
the DT mice the first week after DT administration
surprising; our work with DT up to this point had demonstrated no gross behavioral 
change in other cohorts of mice, 
when observing these mice. This data was disconcerning because we were now unsure of 
whether the PPI reduction in the DT mice was in fact due to neuronal ablation or the 
effects of DT on the complex s
response to loud stimuli after hearing ‘premonitory’ lower amplitude sounds is difficult to 
assess when low baseline startle amplitude 
delivered on their own.  
Graph 2. Startle data for AAV-injected mice. Startle reductions in high
data and left us unsure as to whether DT effects or interneuron ablation were the cause for PPI reductions.
denote separate and sequential periods of startle recording to pulse
 
reduction in startle amplitude was demonstrated in 
 as demonstrated in graph 2
nor was there evidence for any overt behavioral changes 
tartle circuitry in general. Prepulse inhibition of startle 
results from the high amplitude stimuli 
-dose DT treated mice confounded our PPI 
-only conditions. 
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 Blocks 
 To test the nonspecific effect of this high dose of DT on startle and PPI, we 
administered high-dose DT to wild
virus. This would demonstrate 
reduction and whether it also reduced PPI in the absence of AAV virus injection. The 
data obtained in this analysis is presented in the two following graphs.
Graph 3. Startle data for high-dose DT
seen similarly to those seen in the cohort of AAV
startle recording to pulse-only conditions.
 
We saw the same redu
week after their DT administration (demonstrating to us that the DT was 
of reduced startle). DT in fact had some role in disrupting the complex startle circuitry; 
however, with startle values in the 100
a change in PPI for these mice
PPI reduction seen in the AAV
-type mice that had not been injected with the AAV 
to us whether the DT was in fact the cause of the startle 
 
 injected wild type mice which received no AAV virus. Startle reductions are 
-injected mice. Blocks denote separate and sequential periods of 
 
ction in startle amplitude in these wild type mice the first 
-300 range, we investigated whether there was also 
, in order to determine if the DT was in fact the cause of 
-injected mice. 
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likely the cause 
 Graph 4 presents the PPI analysis for these hig
appeared to be no loss of PPI in these mice after DT administration.  This encouraged us 
to think that, despite its effects on startle, high
its own in wild-type mice. Rather, this p
reduction seen in virus-
specific effect of neuronal ablation, albeit confounded by the reduction in baseline startle.
Graph 4. PPI data for high-dose DT injected wild type mice.
improvement in PPI up to four weeks post
 
As described above, we administered a lower dose of DT to two of our control 
mice (#1 and #2) five weeks post
without affecting baseline startle. 
h-dose DT wild type mice. There 
-dose DT did not necessarily reduce PPI on 
rovided some evidence for the notion that PPI 
injected mice after high-dose DT might indeed represent a 
  Despite the small n, there appeared to be an 
-operatively, in contrast to the virus-injected mice. 
-operatively in an effort to achieve interneuron ablation 
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 PPI data for the late, low
These mice received the same surgery at week 0 as the other 
experiment. No intervention was performed on them from weeks 1
analyses that provided data for left
PPI, the mice were injected with the 4ng DT as described. This produced a striking effect 
noted in mouse 1, but no overt effect on PPI in mouse 2. 
further examined in an immunohistological analyse
 
Using DAB staining 
specimens under light microscopy, we 
of the ChAT interneurons. 
data for control mouse #
number of striatal ChAT interneurons is 
prominent and stable, as was 
Figure 25. PPI data for the two mice injected with low
-dose DT injected mice are presented in figure 25 
transgenic 
-5, except for the PPI 
-most points on these graphs. Then, after the week 5 
The causes of which were 
s of the brains of these mice.
to identifying the ChAT interneurons, and observing the 
were able to clearly see the dark staining
In Figure 26 on the following page, the immunohistochemical 
8 is demonstrated alongside its PPI data. No reduction in the 
documented in this mouse
previously demonstrated in this section. 
-dose DT, five weeks after bilateral AAV virus injection
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below. 
mice of this 
 
 pattern 
 and the PPI is 
 
 Figure 26. Immunostaining of the striatal ChAT interneurons 
in control mouse #8 injected with AAV but not with DT.
 In figure 27, the data is presented for 
mouse 3, which received high
 
Figure 27. Immunostaining of the striatal ChAT 
interneurons in mouse #3, injected with AAV 
and then high-dose DT 2 weeks post
operatively 
-dose DT 2 weeks post-operatively.  
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  Next, we examined the immunohistochemistry of the two low
mice in order to determine the cause for a 
#2. The striatal image for mouse #1 is presented in figure 28, demonstrating an ablation 
of a substantial portion of ChAT interneuron
relative preservation of inter
most resemble findings of interneuron loss in patients with TS, w
reduction has been seen. 
 
 
 
 
 
 
 
 Finally, the data for mouse #2 
relative preservation of the striatal interneurons, like
#8. It is possible that the virus was not 
mouse, the DT did not properly apoptose the infected interneurons, or
-dose DT injected 
reduction in PPI in mouse #1 but not in mouse 
s localized in the dorsomedial striatum, but a 
neurons in more lateral regions. This ablation 
here only a 50
are presented in figure 29. There appears to be a 
ned to the data for the control mouse 
originally injected on target to the 
Figure 28. Immunostaining of the striatum of mouse #1 
which was injected with low-dose DT 5 weeks post
operatively. The loss of interneurons appears to be 
localized in the dorsomedial striatum.
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could possibly 
-60% 
striatum in this 
 there was yet 
-
 
 another reason why these neurons were not ablated, but
PPI data in this mouse is consistent with the documented ineffective ablation of these 
interneurons as seen on immunohistochemistry
closely with mouse #1, demonstrated 
of the interneurons thought to
by these new findings which were the fi
DTR/DT system in vivo. 
 
 
 
 
 
 
 
 despite these potentialities,
. The data for this mouse, compared 
that PPI behavioral changes correlat
 regulate this behavior in striatum. Our group
rst to demonstration the full efficacy of our 
Figure 29. Immunostaining of the striatum of 
mouse #2 which was injected with low
5 weeks post-operatively. No substantial loss of 
interneurons correlated with the intact PPI 
behavior.
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 the 
ed with the loss 
 was excited 
-dose DT 
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.  
IV. Discussion 
 
Tourette syndrome is a highly complex human neuropsychiatric disorder which, for 
some individuals, creates a high degree of morbidity. Recent findings demonstrate a 
specific and significant 50-60% reduction of striatal interneurons in individuals who 
experienced the most severe forms of the sensorimotor-gating disruption associated with 
TS and its related disorders. Viral vector-mediated gene delivery is a technological 
achievement, which when used in transgenic mice, allows for a cell-type specificity never 
before realized. Its application for modeling the pathophysiological findings in TS, which 
implicate striatal interneuron loss in sensorimotor dysfunction, will allow us to 
understand the neurocircuitry of the striatum in unprecedented ways. This model will also 
allow us to observe naturally-occurring compensatory mechanisms surrounding the 
disruption of these regulatory cells, as well as understand the downstream neurochemical 
changes which may one day drive the development of novel therapeutics aimed at 
correcting symptomatology in Tourette syndrome.  
Studying previously established protocols for assessing pharmacological effects on 
behavioral PPI data can also inform the direction of future studies, such as testing the 
effects of anti-psychotic medications on this mouse model in development. (85, 86) This 
work will undoubtedly be performed in parallel to further behavioral characterization of 
these mice. As we understand more about the circuitry of PPI, now thought to reside in 
the limbic cortex, striatum, pallidum and pontine tegmentum, we can begin to tease apart 
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the function of each nucleus in this circuit, understand exactly what role our lesions are 
having, and where pharmacological therapeutics can intervene.  (87) 
I took a lead role in performing a majority of the work throughout the course of this 
project. Testing of the iDTR1 construct occurred before my time in the lab, but I 
constructed both the iDTR2 and iDTR3 plasmids, tested them extensively in vitro and in 
vivo, and performed behavioral analyses on the first cohort of iDTR3-injected mice. 
Mouna Basr performed the in vitro testing of the iDTR2 plasmid in primary neuronal 
culture and the subsequent MTT cell death assay on these cells. Meiyu Xu helped in the 
planning of the in vitro and in vivo testing of both the iDTR2 and iDTR3 plasmids, and 
performed the saporin toxin injections on the wild type mice on her own. Other than these 
exceptions, I conducted the remainder of the work detailed in this report. 
I greatly valued my experience working on this project and it was a personal 
accomplishment to demonstrate such striking correlation between behavioral assays and 
relative degrees of interneuron loss on immunohistochemistry in this small cohort of 
mice. For me, it truly brought this project full circle.  
While some PPI effects may have been diluted between the individual mice within 
the larger groups of mice, the utility of analyzing data for individual mice became 
evident. In fact, while the pooled PPI data for mice #1 and #2 in the low dose-DT 
experiment did not show a difference from that of the control cohort, it was only when 
we looked at mouse #1 separately from mouse #2 were we able to see a reduction in PPI 
for mouse #1, and then correlate it with the immunohistochemistry of the mouse’s brain.  
There were several possible reasons why mouse #2 did not show neuronal ablation 
with low dose DT, including inaccurate stereotactic injection of the virus at week 0, 
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ineffective DTR expression in its interneurons, or just the ineffectiveness of low-dose DT 
in some mice. The relative metabolism of this toxin in different mice and its relative 
variability in permeating the blood-brain barrier may be two causes for its differential 
efficacy between mice. More work remains to be done to study the effects of simian DT 
on our system, as well as in physiological-unique mice. 
We did, however, learn a great deal about DT administration from our wild-type 
control experiment. While previously unknown, we discovered that high-dose DT has a 
significant impact on startle response during PPI analysis. As a result, it is difficult to 
attribute PPI changes in virus-injected mice which subsequently received high-dose DT 
solely to interneuron ablation. Other behavioral factors may come into play, and as a 
result of our ever-evolving hypotheses, we learned to refine our experiment to include a 
low-dose DT injection, which appeared to in fact still work to induce apoptosis in cells 
expressing the DT receptor on their surfaces.  
 
Further Studies 
Other work yet to be performed includes further PPI analysis in a larger 
population of WT mice given high- and low-dose DT in order to determine whether any 
real deficits in startle or PPI presents in these mice. This is a necessary experiment to 
demonstrate first that there are no observable effects on PPI or startle in mice given low-
dose DT. Secondly, it may prove useful in the future to understand what effect high-dose 
DT is having on behavior in a mouse, where the changes are occurring neurobiologically 
(using immunohistochemistry to survey suspected nuclei in the startle circuit), why there 
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appear to be no changes in PPI, and whether the startle reduction seen is only a transient 
phenomenon. 
In addition to testing and further understanding the subtle behavioral effects of 
DT administration, another larger cohort of mice will be injected with the AAV-iDTR 
virus in order to replicate findings from this current experiment and optimize conditions 
for interneuron ablation (this is actually already underway).  Additionally, the PPI data 
will be looked at very closely on an individual basis in this new cohort in order to further 
determine any dose-response correlation that may exist between interneuron loss as seen 
by immunohistochemistry and quantitative deficits documented in PPI behavior. It would 
indeed be a fascinating finding to demonstrate a stepwise degree of PPI dysfunction with 
quantitated neuronal loss, or loss localized to a specific striatal region. This larger cohort 
will also serve as the basis to further study the generation of ChAT interneuron-deficient 
mice both behaviorally and pharmacologically to determine the efficiency of this model, 
its responsiveness to antipsychotics and amphetamine, and its predictive validity in 
replicating the symptomatology of TS. 
The additional behavioral analyses to be undertaken in DT-administered, virus-
injected mice will included the use of a Cleversys apparatus in order to systematically 
observe any behavioral effects on the mice which may produce repetitive, stereotypic 
behavioral, similar to that of TS. The Cleversys apparatus monitors the details of each 
mouse’s movements over the course of 24 hours and is a highly sophisticated movement-
tracking program which catalogues each of the mouse’s behaviors. It has an extraordinary 
capacity to document even the most subtle increases in stereotypic behavior between 
different cohorts of mice. While some individuals with TS demonstrate severe and overt 
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ticcing behaviors, there are in fact many subtle gradations of behavioral manifestation 
which require a highly sensitive observer in order to reliably qualify and quantify. The 
Cleversys apparatus will serve this purpose, as highly-trained clinicians do for individuals 
with TS. 
In addition to this analysis, it would be useful to observe cohorts of mice from 
subsequent experiments in an elevated-plus maze and an open field analysis. The former 
documents the amount of time a mouse spends on an open platform two feet off the 
ground as compared to closed platforms on the same structure, organized in a “plus” 
shape. This is a well-documented behavioral assay that has been used to assess anxiety-
like behaviors in mice. (88, 89) It is conceivable that with changes in the fear-induced 
startle response, changes in other emotionally-related systems may also occur. 
Additionally, the open field analysis is performed by placing the mouse in a square box 
and using software to assess the video of a 5-minute trial of this mouse in this box. The 
amount of time the mouse spends in the periphery of the box, as compared to its center, 
has been used as a relative measure of anxiety-like versus exploratory-like behaviors in 
various mouse models. (90) These two tests will provide useful information regarding the 
anxiety-like behaviors of the virus-injected mice and determine if in fact startle of PPI 
data can in any way be influenced by the differences in anxiety between the cohorts of 
mice.  
The use of amphetamines has also been used to induce tic-like behaviors in mice. (91) 
Testing the response of experimental mice in our model with amphetamines may provide 
insight into the sensorimotor gating abnormalities in these mice, and may accentuate 
more subtle behavioral changes related to TS.   
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With further reliability of behavioral testing, mice will also be administered 
medications classically known to reduce symptoms in TS, such as typical and atypical 
antipsychotics. This measure would allow us to further validate the face validity of our 
model and demonstrate a degree of predictive validity in support of trialing novel 
therapeutics for the alleviation of symptoms, similarly to the effects of the antipsychotic 
medications on patients with Tourette syndrome.  
 
Limitations 
The biggest limitations imposed on me during the course of this study were time and 
availability of transgenic mice. This was originally planned to be a several year project, 
and while we were able to achieve much in the 18 months chronicled in this report, there 
is a great deal that still remains to be done. It is wonderful that behavioral consequences 
of our DTR/DT system are just now being documented and correlated to interneuron loss, 
but indeed I look forward to taking time over the next few months to increase the sample 
size of the virus injected mice, optimize further DT administration in order to minimize 
any unwanted behavioral consequences, localize injection to different parts of the 
striatum (dorsal and lateral), and steadily demonstrate behavioral changes across several 
cohorts of mice alongside their immunostaining data. Additionally, strain differences 
between control mice and our transgenic mice could result in different behavioral 
responses as seen on PPI. This study is also limited in its goals to produce a model for a 
highly complex, cognitive as well as sensorimotor disorder, which can only fully be 
experienced in a human. While symptom such as tics and PPI dysfunction can be 
replicated, the internal cognitive and emotional struggle faced by patients, which also 
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interact and change behavioral manifestations, can never be modeled fully in mice. 
Finally, while we can observe DTR expression in infected interneurons, and then 
interneuron loss after DT administration, these are only indirect ways of understanding 
exactly what mechanisms are occurring at the cellular level to truly cause these apoptotic 
events. While it appears our hypotheses are correct, and result in our predicted outcomes, 
I am certain that there remains much we do not understand regarding what is occurring at 
the cellular and subcellular levels. As we replicate this interneuron loss more in the 
future, we will further investigate some of the mechanisms and downstream effects 
taking place. 
 
Conclusion 
We were able to engineer several AAV-vector plasmids which utilized sophisticated 
recombination techniques to allow for the selective expression of the DTR gene in the 
presence of cre. We were able to use the genetic machinery of PC12 cells, as well as 
primary neural culture cells to demonstrate effective DTR expression after transfection of 
this construct into these cells. In addition, translation of this work was performed 
demonstrating the effectiveness of the DTR-expressing system in vivo as well. Finally, 
we are starting to document real behavioral modifications induced through the genetic 
engineering and ablation of a small population of interspersed interneurons that comprise 
only 1% of the total volume of the striatum. We have been fortunate enough to describe 
these behavioral changes side-by-side with images demonstrating the loss of ChAT 
interneurons in our small pilot study of nine mice. This finding is quite exciting, unique 
in its quite novel methodology, and will surely fuel work on this project for years to 
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come. Further directions can include investigating the potential of this system to ablate 
other populations of interneurons and understand the downstream effects on global 
striatal activity. 
I am grateful to have work on such an interesting and internally-motivating project in 
an environment such as Dr. Pittenger’s lab. I valued the time spent working with Meiyu 
Xu and the guidance provided to me during the course of this work by Dr. Pittenger. 
Especially during the several months when I took the lead role on this initiative while 
Meiyu was away on maternity leave, Dr. Pittenger’s support was unparalleled and it 
provided me the self-confidence to manage such complex work and produce results that 
propelled it forward. I am certain that the skills I gained during this year will allow me to 
further study the use of viral vector-mediated gene therapy in the future and advance its 
use in correcting identified neuropathophysiology in any number of other psychiatric and 
neurological disorders. It is certainly one of the most rewarding experiences of my time 
at the Yale School of Medicine. 
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